Mirum Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $521.3M | $336.9M | $186.4M | $77.1M | $19.1M | $0 | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | $257.0M | $202.2M | $145.9M | $89.1M | $59.2M | $22.7M | $11.8M |
| Operating Income | — | $-22.1M | $-87.6M | $-109.2M | $-131.2M | $-173.4M | $-104.3M | $-54.7M |
| Operating Margin | — | -4.2% | -26.0% | -58.6% | -170.3% | -906.1% | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-21.4M | $-86.9M | $-162.4M | $-142.1M | $-84.0M | $-103.3M | $-52.5M |
| Income Tax Expense | — | $1.9M | $1.0M | $991.0K | $-6.4M | $37.0K | $6.0K | $21.0K |
| Net Income | — | $-23.4M | $-87.9M | $-163.4M | $-135.7M | $-84.0M | $-103.3M | $-52.6M |
| Net Margin | — | -4.5% | -26.1% | -87.7% | -176.0% | -438.9% | — | — |
| EPS (Basic) | — | $-0.47 | $-1.85 | $-4.00 | $-4.01 | $-2.77 | $-4.09 | $-4.58 |
| EPS (Diluted) | — | $-0.47 | $-1.85 | $-4.00 | $-4.02 | $-2.77 | $-4.09 | $-4.58 |
| Shares Outstanding (Basic) | 60.3M | 50.2M | 47.5M | 40.9M | 33.8M | 30.3M | 29.8M | 22.6M |
| Shares Outstanding (Diluted) | 60.3M | 50.2M | 47.5M | 40.9M | 34.0M | 30.3M | 29.8M | 22.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |
People who invest make money for themselves; people who speculate make money for their brokers.